The effect of dwell volume on chromatographic selectivity can be successfully modelled using retention prediction software. Hence, the robustness of reversed-phase LC gradient methodologies, with respect to dwell volume, can be conveniently assessed.
Monoclonal antibodies (mAbs) are being developed at an explosive rate and have attracted great interest from both smaller biotech firms and big pharmaceutical companies. Developing mAbs and next-generation antibody–drug conjugates (ADCs) is highly demanding in many ways. From an analytical perspective, handling mAbs and ADCs presents many new challenges. This article describes how size-exclusion chromatography (SEC) combined with high-resolution mass spectrometry (HRMS) can be applied to the detailed characterization of mAbs and ADCs.
Tomas Cajka previews his keynote lecture at HPLC 2019, where he will introduce an LC−MS workflow (LIpids, Metabolites and eXposome compounds [LIMeX]) for simultaneous extraction of complex lipids, polar metabolites, and exposome compounds that combines LC–MS targeted and untargeted analysis.
Davy Guillarme previews his presentation at HPLC 2019 highlighting the new trends in LC×LC applied for biopharmaceutical characterization, including the hyphenation with high‑resolution mass spectrometry (HRMS) and ion mobility spectrometry (IMS).
Wouldn’t it be nice if a single generic high performance liquid chromatography (HPLC) method could be used for all small molecule drugs - not only for potency assays but also for ICH-compliant stability-indicating assays?